Gilead Sciences, Inc. (NEO:GILD)

Canada flag Canada · Delayed Price · Currency is CAD
23.28
-0.03 (-0.13%)
Sep 2, 2025, 3:45 PM EDT
-0.13%
Market Cap192.85B
Revenue (ttm)39.37B
Net Income (ttm)8.61B
Shares Outn/a
EPS (ttm)6.83
PE Ratio22.41
Forward PE13.34
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume4,528
Open23.33
Previous Close23.31
Day's Range23.11 - 23.33
52-Week Range20.08 - 25.02
Betan/a
RSI43.81
Earnings DateNov 6, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 17,600
Stock Exchange Cboe Canada
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

There is no news available yet.